1.
World Health Organization. Prevention of blindness and visual impairment. WHO. 2019. http://
www.who.int/blindness/causes/priority/en/. Accessed Dec 2019.
2.
Yamada M, Hiratsuka Y, Roberts CB, et al. Prevalence of visual impairment in the adult Japanese
population by cause and severity and future projections. Ophthalmic Epidemiol. 2010;17:50–7.
3.
Ferris FL 3rd, Fine SL, Hyman L. Age-related macular degeneration and blindness due to neovascular
maculopathy. Arch Ophthalmol. 1984;102:1640–2.
4.
Ambati J, Fowler BJ. Mechanisms of age-related
macular degeneration. Neuron. 2012;75:26–39.
5.
Aiello LP, Avery RL, Arrigg PG, et al. Vascular
endothelial growth factor in ocular fluid of patients
with diabetic retinopathy and other retinal disorders. N Engl J Med. 1994;331:1480–7.
6.
Freund KB, Korobelnik JF, Devenyi R, et al. Treatand-extend regimens with anti-VEGF agents in
retinal diseases: a literature review and consensus
recommendations. Retina. 2015;35:1489–506.
7.
Lanzetta P, Loewenstein A, Vision Academy Steering Committee. Fundamental principles of an antiVEGF treatment regimen: optimal application of
intravitreal anti-vascular endothelial growth factor
therapy of macular diseases. Graefes Arch Clin Exp
Ophthalmol. 2017;255:1259–73.
8.
Maguire MG, Martin DF, Ying GS, et al. Five-year
outcomes with anti-vascular endothelial growth
factor treatment of neovascular age-related macular
degeneration: the comparison of age-related macular degeneration treatments trials. Ophthalmology. 2016;123:1751–61.
9.
Patel PJ, Devonport H, Sivaprasad S, et al. Aflibercept treatment for neovascular AMD beyond the
first year: consensus recommendations by a UK
expert roundtable panel, 2017 update. Clin Ophthalmol. 2017;11:1957–66.
10. Rezaei KA. Global trends in retina. Chicago: American Society of Retina Specialists; 2016.
11. Koh A, Lanzetta P, Lee WK, et al. Recommended
guidelines for use of intravitreal aflibercept with a
treat-and-extend regimen for the management of
neovascular age-related macular degeneration in
the Asia–Pacific region: report from a consensus
panel. Asia–Pacific J Ophthalmol. 2017;6:296–302.
12. Heier JS, Brown DM, Chong V, et al. Intravitreal
aflibercept (VEGF trap-eye) in wet age-related
Adv Ther
macular degeneration. Ophthalmology. 2012;119:
2537–48.
macular degeneration. Invest Ophthalmol Vis Sci.
2017;58:406.
13. Schmidt-Erfurth U, Kaiser PK, Korobelnik JF, et al.
Intravitreal aflibercept injection for neovascular
age-related macular degeneration: ninety-six-week
results of the VIEW studies. Ophthalmology.
2014;121:193–201.
21. Berg K, Hadzalic E, Gjertsen I, et al. Ranibizumab or
bevacizumab for neovascular age-related macular
degeneration according to the Lucentis compared
to Avastin study treat-and-extend protocol: twoyear results. Ophthalmology. 2016;123:51–9.
14. Cohen SY, Mimoun G, Oubraham H, et al. Changes
in visual acuity in patients with wet age-related
macular degeneration treated with intravitreal
ranibizumab in daily clinical practice: the LUMIERE
study. Retina. 2013;33:474–81.
22. Silva R, Berta A, Larsen M, et al. Treat-and-extend
versus monthly regimen in neovascular age-related
macular degeneration: results with ranibizumab
from the TREND study. Ophthalmology. 2018;125:
57–65.
15. Holz FG, Tadayoni R, Beatty S, et al. Multi-country
real-life experience of anti-vascular endothelial
growth factor therapy for wet age-related macular
degeneration. Br J Ophthalmol. 2015;99:220–6.
23. Yamamoto A, Okada AA, Nakayama M, Yoshida Y,
Kobayashi H. One-year outcomes of a treat-andextend regimen of aflibercept for exudative age-related macular degeneration. Ophthalmologica.
2017;237:139–44.
16. Writing Committee for the UK Age-Related Macular
Degeneration EMR Users Group. The neovascular
age-related macular degeneration database: multicenter study of 92,976 ranibizumab injections:
report 1: visual acuity. Ophthalmology. 2014;121:
1092–101.
17. Zhu M, Chew JK, Broadhead GK, et al. Intravitreal
ranibizumab for neovascular age-related macular
degeneration in clinical practice: five-year treatment outcomes. Graefes Arch Clin Exp Ophthalmol. 2015;253:1217–25.
18. Fauser S, Muether PS. Clinical correlation to differences in ranibizumab and aflibercept vascular
endothelial growth factor suppression times. Br J
Ophthalmol. 2016;100:1494–8.
19. Fauser S, Schwabecker V, Muether PS. Suppression
of intraocular vascular endothelial growth factor
during aflibercept treatment of age-related macular
degeneration. Am J Ophthalmol. 2014;158:532–6.
20. Do DV, Nguyen QD. Pharmacokinetics of free
aflibercept in patients with neovascular age related
24. Gillies MC, Hunyor AP, Arnold JJ, et al. Effect of
ranibizumab and aflibercept on best-corrected
visual acuity in treat-and-extend for neovascular
age-related macular degeneration: a randomized
clinical trial. JAMA Ophthalmol. 2019;137:372–9.
25. Guymer RH, Markey CM, McAllister IL, Gillies MC,
Hunyor AP, Arnold JJ. Tolerating subretinal fluid in
neovascular age-related macular degeneration treated with ranibizumab using a treat-and-extend
regimen: FLUID study 24-month results. Ophthalmology. 2019;126:723–34.
26. Wykoff CC, Ou WC, Brown DM, et al. Randomized
trial of treat-and-extend versus monthly dosing for
neovascular age-related macular degeneration:
2-year results of the TREX-AMD study. Ophthalmol
Retina. 2017;1:314–21.
27. Ogura Y, Terasaki H, Gomi F, et al. Efficacy and
safety of intravitreal aflibercept injection in wet
age-related macular degeneration: outcomes in the
Japanese subgroup of the VIEW 2 study. Br J Ophthalmol. 2015;99:92–7.
...
論文の公開元へ
